Vittorio Stefoni1,2, Lisa Argnani2, Matteo Carella2, Beatrice Casadei2, Alice Morigi2, Ginevra Lolli2, Alessandro Broccoli1,2, Cinzia Pellegrini1, Laura Nanni2, Paolo Elia Coppola2, Pier Luigi Zinzani3,4. 1. IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. 2. Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy. 3. IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. pierluigi.zinzani@unibo.it. 4. Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it.
Abstract
PURPOSE: One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage regimen able to induce this status without severe toxicity would represent a major achievement in this setting. METHODS: A single-center retrospective study was conducted to assess effectiveness and safety of BEGEV (bendamustine, gemcitabine, and vinorelbine) regimen as first salvage setting prior to ASCT in HL patients. RESULTS: Forty-three patients were treated in our institution between October 2017 and November 2020. Median age at BEGEV therapy was 35.0 years (range 17.2- 70.0), and the median time from frontline therapy to the first cycle of BEGEV was 79.5 days (range 4-2267). At the end of treatment, 31 patients achieved a complete response (CR), with an overall response rate of 76.7%. Forty-one patients harvested CD34+ cells and 35/43 (81.4%) patients underwent ASCT. With a median follow-up of 22 months, 4 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34 months. The estimated 2-year progression-free survival was 66.7%. Response to first-line chemotherapy did not significantly influence prognosis. CONCLUSIONS: BEGEV regimen was well tolerated, and reversible haematological toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells.
PURPOSE: One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage regimen able to induce this status without severe toxicity would represent a major achievement in this setting. METHODS: A single-center retrospective study was conducted to assess effectiveness and safety of BEGEV (bendamustine, gemcitabine, and vinorelbine) regimen as first salvage setting prior to ASCT in HL patients. RESULTS: Forty-three patients were treated in our institution between October 2017 and November 2020. Median age at BEGEV therapy was 35.0 years (range 17.2- 70.0), and the median time from frontline therapy to the first cycle of BEGEV was 79.5 days (range 4-2267). At the end of treatment, 31 patients achieved a complete response (CR), with an overall response rate of 76.7%. Forty-one patients harvested CD34+ cells and 35/43 (81.4%) patients underwent ASCT. With a median follow-up of 22 months, 4 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34 months. The estimated 2-year progression-free survival was 66.7%. Response to first-line chemotherapy did not significantly influence prognosis. CONCLUSIONS: BEGEV regimen was well tolerated, and reversible haematological toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells.
Authors: T Baetz; A Belch; S Couban; K Imrie; J Yau; R Myers; K Ding; N Paul; L Shepherd; J Iglesias; R Meyer; M Crump Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: C H Moskowitz; S D Nimer; A D Zelenetz; T Trippett; E E Hedrick; D A Filippa; D Louie; M Gonzales; J Walits; N Coady-Lyons; J Qin; R Frank; J R Bertino; A Goy; A Noy; J P O'Brien; D Straus; C S Portlock; J Yahalom Journal: Blood Date: 2001-02-01 Impact factor: 22.113
Authors: Sally Arai; Michelle Fanale; Sven DeVos; Andreas Engert; Tim Illidge; Peter Borchmann; Anas Younes; Franck Morschhauser; Alex McMillan; Sandra J Horning Journal: Leuk Lymphoma Date: 2013-06-05
Authors: D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: Alison J Moskowitz; Joachim Yahalom; Tarun Kewalramani; Jocelyn C Maragulia; Jill M Vanak; Andrew D Zelenetz; Craig H Moskowitz Journal: Blood Date: 2010-08-23 Impact factor: 22.113
Authors: A Josting; C Rudolph; M Reiser; M Mapara; M Sieber; H H Kirchner; B Dörken; D K Hossfeld; V Diehl; A Engert Journal: Ann Oncol Date: 2002-10 Impact factor: 32.976
Authors: Ryan D Gentzler; Andrew M Evens; Alfred W Rademaker; Bing B Weitner; Bharat B Mittal; Gary L Dillehay; Adam M Petrich; Jessica K Altman; Olga Frankfurt; Daina Variakojis; Seema Singhal; Jayesh Mehta; Stephanie Williams; Lynne Kaminer; Leo I Gordon; Jane N Winter Journal: Br J Haematol Date: 2014-03-15 Impact factor: 6.998